AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

AC Immune S.A.NASDAQ: ACIU

Effect of Forex Changes · Q4 FY2025 · quarter ended Dec 2025

Effect of forex changes turns negative

Q4 FY2025 effect of forex changes was -CHF 60.84K, compared with CHF 1.95M a year earlier. Trailing-twelve-month effect of forex changes was -CHF 2.62M. Over 3 fiscal years it compounded at +42.7% a year.

Context

  • Effect of forex changes amounted to 42.4% of revenue in FY2025, up 36.3 pp from a year earlier.
  • Effect of forex changes increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly effect of forex changes holds near -CHF 60.84K or moves back toward the trailing-twelve-month quarterly average of -CHF 655.21K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CHF 60.84K+305.6% QoQ
Last fiscal yearDec 2025
CHF 1.51M+191.7% YoY
LTMDec 2025
-CHF 2.62M+58.7% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-103.1%——
1 year+191.7%——
3-year CAGR+42.7%——
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

CHF · from the cash flow

Latest · FY2025
1.51M CHF
Year-over-year change
+191.7%

Effect of Forex Changes vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +58.7% is the 3rd highest of 9, against a peer median of -35.7%.
  • Effect of forex changes amounts to 73.4% of revenue for ACIU, versus a peer median of 5.9%.
ACIU Competitors
Effect of Forex Changes for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACIUAC Immune S.A.LTM Dec 2025CHF 2.62M CHF+58.7%+42.7%73.4%
MREOMereo BioPharma Group plcLTM Mar 2026$770K USD+3.4%—154.0%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$501K USD-57.2%——
CLLSCellectis S.A.LTM Mar 2026$386.65K USD+136.0%—0.6%
SLNSilence Therapeutics plcLTM Mar 2026$54K USD——5.9%
AMRNAmarin Corporation plcLTM Mar 2026$43.44K USD-276.5%+114.6%0.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026$24K USD-14.3%+7.7%—
ANNXAnnexon, Inc.LTM Mar 2026$3K USD+200.0%+26.0%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$2K USD-99.9%—6.5%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
Peer median (excluding ACIU) —-35.7%+26.0%5.9%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.